Ceribell to Participate in Upcoming March Investor Conferences
SUNNYVALE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the company will be participating in two upcoming investor conferences. Scott Blumberg, CFO, will present at the upcoming Raymond James 47
Event: Raymond James 47
Date: Monday, March 2, 2026
Time: 1:00 p.m. PST / 4:00 p.m. EST
Event: TD Cowen 46
Date: Tuesday, March 3, 2026
Time: 10:50 a.m. PST / 1:50 p.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at .
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit or follow the company on .
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Media Contact
Brian Price
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
How major US stock indexes fared Friday 3/6/2026
3 Motives to Offload ROCK and One Alternative Stock Worth Purchasing

Crescent Biopharma Announces Grants of Inducement Awards

NI Holdings, Inc. Reports Results for Fourth Quarter and Year Ended December 31, 2025

